Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 8 results.
User Information
Export Records
  1. 1.   Neovascular pruning by IDO1 inhibitors can potentiate immunogenic cytotoxicity of ischemia-targeted agents to synergistically enhance anti-PD-1 responsiveness
  2. Shen, Shih-Chun; Dey, Souvik; DuHadaway, James B; Sutanto-Ward, Erika; Hampton, Maurice T; Kozlov,Serguei; Prendergast, George C; Muller, Alexander J
  3. Journal for Immunotherapy of Cancer. 2025, May 30; 13(5):
  1. 2.   Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterization
  2. Becker, William; Olkhanud, Purevdorj B; Seishima, Noriko; Moreno, Paloma A; Goldfarbmuren,Kate; Maeng, Hoyoung M; Berzofsky, Jay A
  3. Journal for Immunotherapy of Cancer. 2024, Jul 01; 12(7):
  1. 3.   First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Ra, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
  2. Leidner, Rom; Conlon, Kevin; McNeel, Douglas G; Wang-Gillam, Andrea; Gupta, Sumati; Wesolowski, Robert; Chaudhari, Monica; Hassounah, Nadia; Lee, Jong Bong; Ho Lee, Lang; O'Keeffe, Jessica A; Lewis, Nancy; Pavlakis,George; Thompson, John A
  3. Journal for Immunotherapy of Cancer. 2023, Oct; 11(10):
  1. 4.   Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
  2. Merino, Diana M; McShane, Lisa M; Fabrizio, David; Funari, Vincent; Chen, Shu-Jen; White, James R; Wenz, Paul; Baden, Jonathan; Barrett, J Carl; Chaudhary, Ruchi; Chen,Li; Chen, Wangjuh Sting; Cheng, Jen-Hao; Cyanam, Dinesh; Dickey, Jennifer S; Gupta, Vikas; Hellmann, Matthew; Helman, Elena; Li, Yali; Maas, Joerg; Papin, Arnaud; Patidar,Rajesh; Quinn, Katie J; Rizvi, Naiyer; Tae, Hongseok; Ward, Christine; Xie, Mingchao; Zehir, Ahmet; Zhao, Chen; Dietel, Manfred; Stenzinger, Albrecht; Stewart, Mark; Allen, Jeff
  3. Journal for immunotherapy of cancer. 2020, Mar; 8(1): pii: e000147..
  1. 5.   rhIL-15 and anti-PD-L1 combination therapy expands a CXCR3+PD1-/low CD8 T cell subset in SIV-infected rhesus macaques
  2. Chen, Ping; Chen, Hui; Moussa, Maha; Cheng, Jie; Li, Tong; Qin, Jing; Lifson,Jeffrey; Sneller, Michael C; Krymskaya,Ludmila; Godin, Steven; Lane, H Clifford; Catalfamo, Marta
  3. The Journal of infectious diseases. 2020, Feb 15; 221(4): 523-533.
  1. 6.   A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses
  2. Zimmer, Alexandra S; Nichols,Erin; Cimino-Mathews, Ashley; Peer, Cody; Cao, Liang; Lee, Min-Jung; Kohn, Elise C; Annunziata, Christina M; Lipkowitz, Stanley; Trepel, Jane B; Sharma, Rajni; Mikkilineni, Lekha; Gatti-Mays, Margaret; Figg, William D; Houston, Nicole D; Lee, Jung-Min
  3. Journal for immunotherapy of cancer. 2019, Jul 25; 7(1): 197.
  1. 7.   Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases
  2. Ranjan, Surabhi; Quezado, Martha; Garren, Nancy; Boris, Lisa; Siegel, Christine; Lopes Abath Neto, Osorio; Theeler, Brett J; Park, Deric M; Nduom, Edjah; Zaghloul, Kareem A; Gilbert, Mark R; Wu, Jing
  3. BMC Cancer. 2018, Mar 01; 18(1): 239.
  1. 8.   Measuring Tumor Mutational Burden Using Whole-Exome Sequencing
  2. Vilimas,Tomas
  3. Methods in molecular biology (Clifton, N.J.). 2020 2055: 63-91.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel